Stereotaxis Inc

Stereotaxis operates with a cash balance of $13.42 million and no long-term debt, resulting in a debt-to-equity ratio of 0.00. The company's liquidity position is reflected in a current ratio of 1.51, indicating sufficient short-term assets to cover liabilities. However, negative operating cash flow of -$13.69 million and free cash flow of -$21.45 million suggest ongoing cash burn despite a strong cash position. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of $21.64 million on $32.38 million in revenue, resulting in a negative return on equity of -11.56% and return on assets of -4.14%. These results fall well below the typical performance benchmarks for medical equipment firms. Geographically, Stereotaxis derives the majority of its revenue from North America, with over 70% of total revenue coming from the United States. The company's product portfolio is concentrated in robotic catheter systems for cardiac procedures, with limited diversification into other therapeutic areas. This concentration increases exposure to regulatory changes and adoption rates in the U.S. market. The company's growth trajectory shows declining revenue, with a year-over-year contraction in operating income of $22.60 million. Analysts project continued challenges, with no significant revenue acceleration expected in the near term. The mean price target of $4.20 implies potential upside from current levels, but the path to profitability remains uncertain. Risk factors include liquidity constraints from negative operating cash flow and the absence of long-term debt capacity. The company has no immediate dilution risks, with basic and diluted shares outstanding aligned at 97.48 million. However, the need for capital to fund operations could necessitate future equity raises, potentially diluting existing shareholders. Recent filings show no material changes in business operations or capital structure. The company continues to focus on its core robotic navigation systems while managing cash burn through cost control measures. No significant new product launches or strategic acquisitions were disclosed in recent investor communications.